Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2012-03-19
- Target Recruit Count
- 5
- Registration Number
- NCT01136252
- Locations
- 🇪🇸
Servicio de Oftalmologia. Hospital Universitario Vall d'Hebron, Barcelona, Spain
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 261
- Registration Number
- NCT01124838
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT01119859
Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Glostrup University Hospital, Copenhagen
- Target Recruit Count
- 40
- Registration Number
- NCT01029613
- Locations
- 🇩🇰
Dep. of Rheumatology, Glostrup Hospital, Copenhagen, Denmark
🇩🇰Dep. of medicine, Herlev Hospital, Copenhagen, Denmark
🇩🇰Dep. of Radiology, Herlev Hospital, Copenhagen, Denmark
Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 49
- Registration Number
- NCT01029847
- Locations
- 🇩🇰
Dep. of Rheumatologym Glostrup Hospital, Copenhagen, Denmark
🇩🇰Dep. of Rheumatology, Helsinør Hospital, Hørsholm, Denmark
🇩🇰Dep. of Radiology, Herlev Hospital, Copenhagen, Denmark
Abatacept Versus Adalimumab Head-to-Head
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 869
- Registration Number
- NCT00929864
- Locations
- 🇺🇸
Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸Arthritis And Rheumatic Disease Specialties, Aventura, Florida, United States
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Rafic Hariri University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00855608
- Locations
- 🇱🇧
Rafic Hariri University Hospital, Beirut, South Beirut, Lebanon
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2021-09-22
- Target Recruit Count
- 63
- Registration Number
- NCT00837434
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- Florida Academic Dermatology Centers
- Target Recruit Count
- 10
- Registration Number
- NCT00827996
Bone Resorption, Osteoclastogenesis and Adalimumab
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Université de Sherbrooke
- Target Recruit Count
- 28
- Registration Number
- NCT00814866
- Locations
- 🇨🇦
Centre de Recherche Clinique Ethienne Lebel, Fleurimont, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.